Sweden-based Alligator Bioscience AB has recruited Anu Balendran to head business development from 1 May. Dr Balendran is joining the company from AstraZeneca Plc where he is external innovation director. He will be responsible for leading Alligator’s preclinical projects towards out-licensing. Dr Balendran holds a PhD in biochemistry.
The appointment follows those of Charlotte Russell as chief medical officer and Peter Ellmark as head of discovery in December 2017 as Alligator prepares a number of drug candidates for the clinic.
Alligator Bioscience announced the appointment on 18 January 2018.
Copyright 2018 Evernow Publishing Ltd